Enovis CORP (ENOV): M&A transaction — Enovis Corp closes acquisition of LimaCorporate for ~€727M cash plus 1.94M shares

Enovis CORP

Completed acquisition of LimaCorporate on Jan 3, 2024 for ~€726.8M cash plus 1,942,686 shares valued at €100M.
Acquisition financed with term loan facility and proceeds from 3.875% convertible senior notes due 2028.
Lima adds 3D-printed Trabecular Titanium implants and comprehensive shoulder revision portfolio.
Enovis' recon segment to reach $1B in revenue, accelerating global growth and margin expansion.
CEO Matt Trerotola highlights strategic acquisition to drive compounding value for shareholders.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Enovis CORP completed an acquisition involving Emil Holding II S.à r.l for cash consideration of approximately €726.8 million, which included the repayment of certain Lima indebtedness, transfer taxes and notarial fees, and 1,942,686 s (closed 2024-01-03).

Action: acquisition
Counterparty: Emil Holding II S.à r.l
Consideration: cash consideration of approximately €726.8 million, which included the repayment of certain Lima indebtedness, transfer taxes and notarial fees, and 1,942,686 s
Closing: 2024-01-03

Exact text from the filing

“Purchase Agreement”) with the Seller, the Company acquired all of the issued and outstanding share capital of Lima from the Seller for (i) cash consideration of approximately €726.8 million, which included the repayment of certain Lima indebtedness, transfer taxes and notarial fees, and (ii) 1,942,686 shares of Enovis common stock, par value $0.001 per share (the

View on SEC.gov

5 m&a transactions filed in the last 30 days. Browse all m&a transactions →

Enovis CORP filing history →

Source: SEC EDGAR

accession 0001193125-24-000976

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.